![]() | ![]() |
Formats:
|
||||||||||||
Copyright © 2008, Cold Spring Harbor Laboratory Press Foxn4 directly regulates tbx2b expression and atrioventricular canal formation 1 Department of Biochemistry and Biophysics, Programs in Developmental Biology, Genetics and Human Genetics, University of California, San Francisco, San Francisco, California 94158, USA; 2 Department of Medicine, University of California, San Francisco, San Francisco, California 94158, USA; 3 Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 94158, USA; 4 Department of Physiology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California 94158, USA 5E-MAIL didier_stainier/at/biochem.ucsf.edu; FAX (415) 476-3892. 6E-MAIL Neil.Chi/at/ucsf.edu; FAX (415) 476-3892. Received October 30, 2007; Accepted January 23, 2008. This article has been cited by other articles in PMC.Abstract Cardiac chamber formation represents an essential evolutionary milestone that allows for the heart to receive (atrium) and pump (ventricle) blood throughout a closed circulatory system. Here, we reveal a novel transcriptional pathway between foxn4 and tbx genes that facilitates this evolutionary event. We show that the zebrafish gene slipjig, which encodes Foxn4, regulates the formation of the atrioventricular (AV) canal to divide the heart. sli/foxn4 is expressed in the AV canal, and its encoded product binds to a highly conserved tbx2 enhancer domain that contains Foxn4- and T-box-binding sites, both necessary to regulate tbx2b expression in the AV canal. [Keywords: Atrioventricular canal, evolutionary development, Forkhead transcription factors, T-box transcription factors, calcium indicator, mutations] The evolution of organs and adaptation of specialized structures utilizes the duplication of highly conserved transcription factors and their cis-regulatory elements. Because of its gradual progression from a single-chambered muscular tube with peristaltic contractility (invertebrates) to a complex multichambered structure with diverse specialized cardiomyocytes (vertebrates), the heart is ideal to study the genetic underpinnings of organogenesis as well as the evolutionary basis of morphological complexity. Division of the heart into chambers represents an essential evolutionary milestone that allows for the heart to receive and pump blood throughout a closed circulatory system (for review, see Olson 2006). Initially, the vertebrate heart develops as a linear tube without significant cellular or physiological differences; however, as the heart tube loops, distinct cardiac chambers begin to develop and acquire high gap junction density leading to faster conduction velocities. In contrast, the atrioventricular (AV) canal and inner curvature regions expand more slowly and maintain characteristics of embryonic tubular hearts including slow conduction velocity (for review, see Moorman and Christoffels 2003). Due to its primitive myocardial nature, the AV canal has evolved several specialized functions in heart formation and function including the formation of AV cushions as well as AV cardiac conduction delay. Here we reveal how these evolutionarily specialized AV structures are coupled developmentally through a novel transcriptional circuit to structurally (AV valves) and functionally (AV conduction delay) separate the atrium and ventricle. Results and Discussion From a recent ENU mutagenesis screen (Beis et al. 2005), we identified a unique cardiovascular mutant, slipjig (sli) (Chen et al. 1996), which displays not only structural AV canal malformations but also AV conduction defects (Fig. 1
To further investigate the cardiac defects, we analyzed sli mutants in several transgenic backgrounds. As visualized in the Tg(cmlc2:ras-GFP)s883; Tg(flk1:ras-cherry)s896 line, which outlines cardiomyocytes and endocardial/endothelial cells in green and red fluorescence, respectively, AV myocardial and endocardial cells display distinct cellular shapes, distinguishing them from chamber myocardial and endocardial cells at 40 hpf (Fig. 1F–K Optical mapping of wild-type hearts reveals that AV conduction delay develops by 36–40 hpf where the AV canal begins to form (Fig. 1L We examined the expression of several cardiac-specific genes to determine how sli affects AV canal formation. Expression of early genes for cardiogenesis (such as nkx2.5 and tbx20) and for myocardial differentiation (such as cmlc2, amhc, and vmhc) appears unaffected in sli mutants (Supplemental Fig. S1). On the other hand, sli mutants exhibit defects in the late expression of several AV canal genes including bmp4, tbx2b, versican, and notch1b. Initially, these AV boundary genes are expressed throughout the anteroposterior extent of the wild-type heart (Walsh and Stainier 2001; Hurlstone et al. 2003). By 48 hpf, the expression of these genes becomes restricted to the AV canal and outflow tract (Fig. 2A,E,I,M
To better understand the molecular nature of the sli phenotype, we positionally cloned the gene disrupted by the sli mutation and found that it encodes the transcription factor Foxn4 (Fig. 3A
Genetic analyses in several species have revealed the crucial role of Tbx genes, including Tbx-1, Tbx-2, Tbx-3, Tbx-5, Tbx-18, and Tbx-20, in multiple aspects of cardiac development (for review, see Stennard and Harvey 2005; Olson 2006). In particular, Tbx2 has been shown to be critical for the patterning and formation of the AV canal as well as the outflow tract (Christoffels et al. 2004; Harrelson et al. 2004; Rutenberg et al. 2006; Kokubo et al. 2007). Interestingly, our analysis of the Tbx2 enhancer across vertebrates revealed perfectly conserved candidate binding sites for Foxn4 (Schlake et al. 1997) as well as Tbx5 (Mori et al. 2006), a transcription factor that regulates the appearance of AV conduction delay (Supplemental Fig. S3; Moskowitz et al. 2007). In electromobility shift assays (EMSA) to test DNA-binding affinity, Foxn4 and Tbx5 bound efficiently to their labeled putative binding sites, and binding was efficiently competed with excess unlabeled cognate competitors, but not with mutated oligonucleotides (Fig. 4A,B
To further test whether Foxn4 and Tbx5 directly regulate tbx2b AV canal expression in vivo, we generated zebrafish transgenics harboring a fluorescent reporter driven by the wild-type tbx2b conserved enhancer or the enhancer with mutations in the Foxn4 or Tbx5 site. The wild-type tbx2b conserved enhancer directed high expression of the dsRed fluorescent reporter in the posterior portion of the fin, nervous tissue, and heart/AV canal and outflow tract, nearly recapitulating the entire endogenous tbx2b expression pattern (Supplemental Fig. S4, cf. A,E and B,F). However, in the mutant Foxn4 site enhancer transgenic, cardiac expression appeared to be absent while fin, brain, and eye expression was maintained (Supplemental Fig. S4C,G). Additionally, the mutant Tbx5 site enhancer transgenic misexpressed the fluorescent reporter throughout the ventricle, while fin, brain, and eye expression was absent (Supplemental Fig. S4D,H). Thus, the putative Foxn4 and Tbx5 DNA-binding sites are required for the precise control of this highly conserved tbx2b enhancer during AV canal development. To determine its role in AV canal formation and function, we performed MO knockdown of tbx2b. tbx2b MO-injected Tg(flk1:gfp)s843, Tg(cmlc2:ras-GFP)s883, and Tg(flk1:ras-cherry)896 embryos exhibited a lack of AV canal formation at 40 hpf, similar to the sli mutant phenotype (Fig. 4D,E Because of this epistatic relationship, we attempted to rescue the slis644 mutant cardiac phenotype with injection of foxn4 and tbx2b mRNA. After injecting foxn4 mRNA, ~55% of slis644 mutant hearts exhibited complete rescue of the AV canal phenotype at 48 hpf (Supplemental Fig. S5A,B), including the pattern of tbx2b expression in the myocardium (Fig. 4G,J Separation of the heart into chambers evolutionarily necessitated the development of specialized structures, such as the cardiac valve leaflets and a cardiac conduction system, to coordinate the beating of these compartments and achieve antegrade blood flow (for review, see Olson 2006). The family of T-box transcription factors has been integral in orchestrating the development of these additional structures (for review, see Stennard and Harvey 2005). Similar to these T-box transcription factors, a cadre of Forkhead transcription factors has recently been shown to be critical for cardiovascular development (Yamagishi et al. 2003; von Both et al. 2004; Wang et al. 2004; Creemers et al. 2006; Ramakrishna et al. 2007). Interestingly, Foxa2, Foxc1, and Foxc2 mediate heart development through direct regulation of Tbx1 (Yamagishi et al. 2003). In our studies, we show that Foxn4, in concert with Tbx5, may exert its transcriptional effect on the regulatory apparatus of Tbx2, directing AV canal formation. Previous reports have indicated that in amniotes the AV myocardium fails to differentiate (de Jong et al. 1992). Our data show that the Foxn4–Tbx2b pathway leads to AV myocardial and endocardial cellular transformations that initiate the development of AV conduction delay and valve leaflets. Whether AV canal defects in Tbx2-null mice (Harrelson et al. 2004) are due to lack of AV cellular changes as observed in foxn4- and tbx2b-defective zebrafish embryos is worth exploring. Interestingly, Foxn4-null mutant mice die perinatally, but their cause of death is unclear (Li et al. 2004). Thus, analyzing how these AV cardiomyocyte changes in zebrafish translate to the mammalian AV specialized myocardium will be of great importance in understanding the evolution of the AV canal as well as human AV conduction block and congenital heart disease. AV canal formation depends on an elaborate cross-talk between specialized myocardial and endocardial cells involving multiple signaling pathways including Wnt/β-catenin, bone morphogenetic protein (BMP), and Notch signaling (Yamada et al. 2000; Hurlstone et al. 2003; Milan et al. 2006; Rutenberg et al. 2006; Kokubo et al. 2007; Xin et al. 2007). BMP2/4 signaling participates in AV canal formation by inducing Tbx2 expression at the AV canal (Yamada et al. 2000), while Notch signaling may suppress this signal in the chambers to restrict Tbx2 expression (Rutenberg et al. 2006; Kokubo et al. 2007; Xin et al. 2007). Our data indicate a possible model in which foxn4 expressed specifically in the AV myocardium directs competent cardiomyocytes at the AV boundary to undergo cellular and molecular changes required for AV myocardial specialization. Wnt/β-catenin or BMP signaling may be the factors that establish this competence at the AV boundary. Alternatively, these signals may directly regulate foxn4 expression or function at the AV canal. Thus, these data provide a mechanistic framework to begin explaining how the combinatorial interactions of the Foxn4 and Tbx5 transcription factors culminate in transcription of Tbx2 to establish the AV boundary. Additionally, because of the complexity of T-box factors and their binding sites, other potential T-box proteins may also regulate tbx2b through the highly conserved Tbx5-binding element in its enhancer. Finally, given that human mutations in TBX5 (Holt-Oram syndrome) lead to cardiac septal and conduction defects (Basson et al. 1997), screening for FOXN4 or TBX2 mutations in humans with heart disease may provide new avenues for understanding the development of congenital heart diseases, leading to future therapeutic or preventive interventions. Materials and methods Zebrafish strains Embryos and adult fish were raised and maintained under standard laboratory conditions. We used the following lines: slis644 (Chi et al. 2008), slitm117c (Chen et al. 1996), Tg(cmlc2:gfp) (Huang et al. 2003), Tg(flk1:gfp)s843 (Jin et al. 2005), Tg(cmlc2:gCaMP)s878 (Arnaout et al. 2007), Tg(cmlc2:dsRed)s879, Tg(cmlc2:ras-GFP)s883 (B. Jungblut, C. Munson, J. Huisken, L.A. Trinh, and D.Y. Stainier, in prep.), Tg(flk1:ras-cherry)s896, Tg(tbx2bpro:dsRed)s899, Tg(cmlc2:tbx2b-P2A-GFP)s900, bicistronic expression of tbx2b and GFP, Tg(tbx2bpro/foxn4MT:GFP)s901, and Tg(tbx2bpro/tbx5MT:cherry)s902. Mapping We mapped the mutation to linkage group 5 using a set of SSLP markers. For fine-mapping, 1241 mutant embryos were tested with SSLP markers in the critical interval (Fig. 3A Histochemical methods Whole-mount in situ hybridization was performed as described previously (Walsh and Stainier 2001; Hurlstone et al. 2003), using the following probes: amhc, vmhc, cmlc2, tbx20, nkx2.5, bmp4, versican, notch1b, foxn4, and tbx2b. For generating sli/foxn4 and tbx2b in situ probes, 750 and 2200 base pairs at the 3′ end of these genes were PCR-amplified. Embryos were embedded in low-melting-point agarose and imaged using either confocal microscopy or conventional fluorescence microscopy. Videorecording/microscopy Bright-field pictures and videos were taken using the Stemi SV11 dissecting microscope (Zeiss). Videos were captured using a standard CCD camera at 20 frames per second (fps). Optical mapping by wide-field epifluorescence Individual zebrafish embryos between 36 and 48 hpf were placed on a coverglass. Images were acquired and data analysis was performed as described previously (Arnaout et al. 2007). Isochronal lines at 60-msec intervals were obtained by identifying the maximal spatial gradient for a given time point. MO antisense oligonucleotide injection and mRNA overexpression We used a MO targeted against an ATG upstream of the translational start site of foxn4 and tbx2b with the following sequence: 5′-CGTG CAGTTTGCTCTGGACGGTCAT-3′ and 5′-GAGCGTGGAAAGG GTGGTAAGCCAT-3′, respectively. Embryos were injected at the one-cell stage with 2 ng of foxn4 or tbx2b MO and assayed between 40 and 48 hpf. For mRNA overexpression, one-cell-stage embryos were injected with 50–150 pg of sli/foxn4 or tbx2b mRNA. EMSAs EMSAs were performed as described previously (De Val et al. 2004). The truncated version of FoxN4, containing the DNA-binding domain, and the full-length Tbx5 were generated from the plasmids pCITE-FoxN4(tr) and pcDNA3-Tbx5, respectively, using the TNT Quick-coupled Transcription/Translation System as described (Promega). The Tbx5 and Foxn4 control and mutant binding sites were adapted as described previously (Schlake et al. 1997; Mori et al. 2006). The sense strand sequences of the tbx2b oligonucleotides used for EMSA were FoxN4tbx2bWT, 5′-GGTT GATTGCTGATTTGACGCTTTTTGGACCAA-3′; FoxN4tbx2bMT, 5′- GGTTGATTGCTGATTTTacaCTTTCTGGACCAA-3′; Tbx5tbx2bWT, 5′GGGGCGTCCGAGAAGGTGTCGGAAGCCTCAGG-3′; Tbx5tbx2bMT, 5′-GGGGCGTCCGAGAAGGatcCGGAAGCCTCAGG-3′. Acknowledgments We thank all the members of the Baier and Stainier laboratory screen teams for their support during the screens; Ana Ayala, Diana Kuo, Justin Bosch, and Koro Brand for expert help with the fish; and Takashi Mikawa and Markus Bussen for critical comments on the manuscript. N.C.C. and R.M.S. are supported by K08 grants (NHLBI), GSK Research and Education Foundation Cardiovascular Awards, and Fellow to Faculty AHA post-doctoral awards. S.D.V. is supported by a fellowship from the AHA. This work was supported in part by grants from the Packard Foundation and the NIH (NHLBI) to D.Y.R.S. Footnotes Supplemental material is available at http://www.genesdev.org. Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1629408. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
Science. 2006 Sep 29; 313(5795):1922-7.
[Science. 2006]Physiol Rev. 2003 Oct; 83(4):1223-67.
[Physiol Rev. 2003]Development. 2005 Sep; 132(18):4193-204.
[Development. 2005]Development. 1996 Dec; 123():293-302.
[Development. 1996]Development. 2005 Sep; 132(18):4193-204.
[Development. 2005]Development. 2006 Mar; 133(6):1125-32.
[Development. 2006]Science. 2001 Aug 31; 293(5535):1670-3.
[Science. 2001]Nature. 2003 Oct 9; 425(6958):633-7.
[Nature. 2003]Development. 2005 Nov; 132(22):4897-910.
[Development. 2005]Science. 2006 Sep 29; 313(5795):1922-7.
[Science. 2006]Dev Dyn. 2004 Apr; 229(4):763-70.
[Dev Dyn. 2004]Development. 2004 Oct; 131(20):5041-52.
[Development. 2004]Development. 2006 Nov; 133(21):4381-90.
[Development. 2006]Dev Dyn. 2004 Apr; 229(4):763-70.
[Dev Dyn. 2004]Development. 2005 May; 132(10):2475-87.
[Development. 2005]Development. 2005 Jun; 132(12):2697-707.
[Development. 2005]Development. 2005 Nov; 132(22):4897-910.
[Development. 2005]Development. 2005 May; 132(10):2463-74.
[Development. 2005]Science. 2006 Sep 29; 313(5795):1922-7.
[Science. 2006]Development. 2005 Nov; 132(22):4897-910.
[Development. 2005]Genes Dev. 2003 Jan 15; 17(2):269-81.
[Genes Dev. 2003]Dev Cell. 2004 Sep; 7(3):331-45.
[Dev Cell. 2004]Development. 2004 Sep; 131(18):4477-87.
[Development. 2004]Dev Biol. 2000 Dec 1; 228(1):95-105.
[Dev Biol. 2000]Nature. 2003 Oct 9; 425(6958):633-7.
[Nature. 2003]Development. 2006 Mar; 133(6):1125-32.
[Development. 2006]Development. 2006 Nov; 133(21):4381-90.
[Development. 2006]Development. 2007 Feb; 134(4):747-55.
[Development. 2007]Development. 1996 Dec; 123():293-302.
[Development. 1996]Dev Dyn. 2003 Sep; 228(1):30-40.
[Dev Dyn. 2003]Development. 2005 Dec; 132(23):5199-209.
[Development. 2005]Proc Natl Acad Sci U S A. 2007 Jul 3; 104(27):11316-21.
[Proc Natl Acad Sci U S A. 2007]Science. 2001 Aug 31; 293(5535):1670-3.
[Science. 2001]Nature. 2003 Oct 9; 425(6958):633-7.
[Nature. 2003]Proc Natl Acad Sci U S A. 2007 Jul 3; 104(27):11316-21.
[Proc Natl Acad Sci U S A. 2007]Dev Biol. 2004 Nov 15; 275(2):424-34.
[Dev Biol. 2004]Proc Natl Acad Sci U S A. 1997 Apr 15; 94(8):3842-7.
[Proc Natl Acad Sci U S A. 1997]Dev Biol. 2006 Sep 15; 297(2):566-86.
[Dev Biol. 2006]